
Acrivon Therapeutics is a precision oncology drug developer whose AP3 proteomics platform generates proprietary OncoSignature diagnostics to identify likely responders.
acrivon.comCrawled Nov 6, 2026
Acrivon Therapeutics names Michail Shipitsin, Ph.D., as SVP of Biomarker Development. He has over 15 years of experience in translational and biomarker research, previously leading teams at Xtuit Pharmaceuticals and Metamark Genetics.
Acrivon Therapeutics appoints Lu Gan, M.D., Ph.D., as SVP of Clinical Development. She has nearly 20 years of experience in oncology drug development, focusing on early-phase trials and biomarker-driven strategies.
Acrivon Therapeutics welcomes Tiffany Crowell as SVP of Clinical Operations. She brings over 30 years of oncology experience, specializing in clinical trial execution and strategic partnerships.
Dr. Santhosh Palani founded PSP Research in 2024 as a healthcare-focused investment firm. Before this, he was an Investment Partner at PFM Health Sciences, investing in biotechnology companies.
Acrivon Therapeutics names Christina Scherer as VP and Head of Early Portfolio Management. She has over 20 years of experience in drug discovery and development, previously leading teams at Anokion US and Kanyos Bio.
The company develops targeted therapies to improve patient outcomes.
Acrivon acquires Aqilion AB’s **Phase 2-ready oral JAK1 inhibitor (ACR-525)** and a **preclinical PKCθ inhibitor program**, entering the **immunology and inflammation (I&I) space** as a new strategic focus. The move complements its existing oncology pipeline, positioning the company to develop treatments for **autoimmune diseases**. The deal expands Acrivon’s therapeutic reach beyond oncology into a high-need area with unmet medical needs.
Acrivon Therapeutics delivers a late-breaking oral plenary presentation and posters at the **38th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics**. The company highlights its **Generative Phosphoproteomics AP3 platform**, used for precision drug discovery and predictive clinical development. Presentations focus on advancements in rational drug design leveraging its proprietary technology.
Acrivon presents early Phase 1/2 clinical trial results for its WEE1/PKMYT1 inhibitor **ACR-2316** in tumors predicted by the AP3 biomarker. The dose-escalation phase data will be shared in a late-breaking oral plenary session at the **38th EORTC-NCI-AACR Symposium**. Timothy A. Yap of **The University of Texas MD Anderson Cancer Center** leads the presentation, scheduled for **November 20, 2026**.
Acrivon’s oral CDK11 inhibitor **ACR-7280** achieves complete tumor regression in preclinical tests using aggressive acute myeloid leukemia (AML) xenograft models. The company targets an IND filing for the AP3-optimized candidate in the first half of 2027, positioning it as a potential first-in-class therapy. Preclinical data highlight its efficacy in treating refractory blood cancers through CDK11 pathway inhibition.
Acrivon Therapeutics names Michaela Levin, Ph.D., as its new Chief Business Officer. The biotech company specializes in precision medicines using its proprietary Generative Phosphoproteomics AP3 platform for drug design and clinical development. Levin’s appointment aims to strengthen Acrivon’s business strategy and operational execution.
Acrivon reports second-quarter 2026 financial results while highlighting key clinical milestones. The company’s **ACR-368** Phase 2b prespecified interim analysis and full serous endometrial cancer (EC) treatment data are expected in the second half of 2026. These updates could provide critical insights into the drug’s efficacy and progression in clinical trials.
Acrivon’s experimental drug **ACR-2316**, a potential first-in-class inhibitor targeting **WEE1/PKMYT1**, enters randomized dose expansion in its Phase 1/2 trial. Early results show a favorable safety profile and sustained single-agent activity, including cases of **lung cancer patients remaining on treatment for over a year** despite prior therapies. The study evaluates efficacy in heavily pretreated subjects, highlighting durable clinical responses.